NCT00710710 - Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2006

Primary Completion Date

October 14, 2008

Study Completion Date

October 14, 2008

Conditions

Pancreatic Neoplasms

Interventions

DRUG

BI 2536

Intravenous Infusion

Trial Locations (10)

1216.10.43001 Boehringer Ingelheim Investigational Site, Vienna

1216.10.49013 Boehringer Ingelheim Investigational Site, Celle

1216.10.49009 Boehringer Ingelheim Investigational Site, Düsseldorf

1216.10.49007 Boehringer Ingelheim Investigational Site, Essen

1216.10.49001 Boehringer Ingelheim Investigational Site, Freiburg/Breisgau

1216.10.49005 Boehringer Ingelheim Investigational Site, Hamburg

1216.10.49010 Boehringer Ingelheim Investigational Site, Herne

1216.10.49008 Boehringer Ingelheim Investigational Site, München

1216.10.49003 Boehringer Ingelheim Investigational Site, Stuttgart

1216.10.49002 Boehringer Ingelheim Investigational Site, Ulm